Overview

Short-term Intravenous Iron Dextran for IDA

Status:
Not yet recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This prospective, randomized, controlled study aims to evaluate the impact of short-term intravenous iron dextran on postoperative recovery and the requirement for allogeneic red blood cells (RBC) transfusion in preoperative Iron-deficiency anemia (IDA) patients receiving orthopedic surgery, thus facilitating developing a simple and effective iron supplement approach for patients' recovery.
Phase:
N/A
Details
Lead Sponsor:
West China Hospital
Treatments:
Dextrans
Iron
Iron-Dextran Complex